- Regorafenib (CAS 755037-03-7) is a potent multi-kinase inhibitor, with its core strength lying in the ability to simultaneously target and inhibit multiple kinase targets related to tumor proliferation, angiogenesis and metastasis, such as VEGFR, PDGFR and KIT. By blocking abnormal signal transduction pathways, it inhibits tumor growth through multiple links to achieve a broad-spectrum anti-tumor therapeutic effect, with a clear mechanism of action and strong targeting specificity.
- Its high-purity chemical properties ensure the stability and consistency of pharmacological effects. Compared with traditional chemotherapeutic drugs, it has lower toxic and side effects and higher patient tolerance. This product is suitable for the clinical treatment of various advanced solid tumors such as colorectal cancer and gastrointestinal stromal tumors, and has important clinical value especially for patients who have failed standard treatment. Meanwhile, it is also an excellent experimental sample for pharmaceutical companies to carry out broad-spectrum targeted drug research and development and scientific research institutions to explore tumor kinase signaling pathways, meeting the dual needs of clinical treatment and scientific research.
Regorafenib/CAS 755037-03-7/Pharmaceutical
$12,000.00
Regorafenib is an active pharmaceutical ingredient (API) primarily used in the formulation of pharmaceutical products for the treatment, prevention, or diagnosis of various diseases and medical conditions.
Be the first to review “Regorafenib/CAS 755037-03-7/Pharmaceutical”
Reviews
There are no reviews yet.